Neuronetics (NASDAQ:STIM) will release its earnings data before the market opens on Tuesday, November 6th. Analysts expect Neuronetics to post earnings of ($0.40) per share for the quarter.
Neuronetics (NASDAQ:STIM) last posted its quarterly earnings results on Tuesday, August 14th. The company reported ($30.60) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.84) by ($29.76). The company had revenue of $13.25 million during the quarter, compared to analyst estimates of $12.20 million. On average, analysts expect Neuronetics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
STIM stock opened at $24.69 on Monday. Neuronetics has a 12-month low of $20.70 and a 12-month high of $39.39.
Several research firms recently issued reports on STIM. BTIG Research reissued a “buy” rating and set a $33.00 price target on shares of Neuronetics in a research report on Thursday, August 16th. JMP Securities increased their target price on Neuronetics from $36.00 to $40.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 15th. Canaccord Genuity increased their target price on Neuronetics from $33.00 to $36.00 and gave the stock a “buy” rating in a research report on Wednesday, August 15th. William Blair assumed coverage on Neuronetics in a research report on Monday, July 23rd. They issued an “outperform” rating on the stock. Finally, Piper Jaffray Companies assumed coverage on Neuronetics in a research report on Monday, July 23rd. They issued an “overweight” rating on the stock. Five analysts have rated the stock with a buy rating, Neuronetics presently has a consensus rating of “Buy” and an average price target of $36.33.
Neuronetics Company Profile
Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders. It offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment for adult patients with major depressive disorder. The company's NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed MRI-strength magnetic field, which induces electrical currents designed to stimulate specific areas of the brain associated with mood.
Recommended Story: What are the reasons investors use put options?
Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.